公开(公告)号：WO2016013829A1

公开(公告)日：2016-01-28

申请号：PCT/KR2015/007513

申请日：2015-07-20

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： AHN, Byoung Ki ,  KO, Ki Seong ,  PARK, So Hyun ,  KI, Min Hyo ,  LIM, Jong Lae

IPC: A61K9/08 ,  A61K31/473 ,  A61K31/573 ,  A61K31/216

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/135 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/5415 ,  A61K31/542 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/28 ,  A61K2300/00

Abstract: Disclosed is a composition comprising a 5α-reductase inhibitor. Forming a liquid crystal upon exposure to an aqueous fluid, the composition can release the 5α-reductase inhibitor at a constant rate over a long period of time. In addition, the composition can significantly alleviate irritations attributed to the topical administration of the 5α-reductase inhibitor, and thus the composition has improved safety.

Abstract translation: 公开了包含5α-还原酶抑制剂的组合物。 在暴露于水性液体时形成液晶，该组合物可以长时间以恒定速率释放5α-还原酶抑制剂。 此外，该组合物可以显着减轻归因于局部施用5α-还原酶抑制剂的刺激，因此组合物具有改善的安全性。

公开(公告)号：WO2014104791A1

公开(公告)日：2014-07-03

申请号：PCT/KR2013/012269

申请日：2013-12-27

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： YOON, Sang Phil ,  KO, Ki Seong ,  YU, Ha Na ,  BAIK, Hye Jung ,  YANG, Won Kyu ,  KO, Jin Young ,  PARK, So Hyun ,  JUNG, Sung Bum ,  AN, Sung Won ,  KI, Min Hyo

IPC: A61K9/20 ,  A61K9/08 ,  A61K9/06 ,  A61K47/30

CPC classification number: A61K47/26 ,  A61K9/0019 ,  A61K9/1075 ,  A61K38/09 ,  A61K47/22 ,  A61K47/24 ,  A61K47/28

Abstract: Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more -OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Abstract translation: 公开了一种药物组合物，其包含：a）至少一种具有至少两个或更多个-OH（羟基）基团的极性头的脱水山梨糖醇不饱和脂肪酸酯; b）至少一种磷脂; c）至少一种不含可离子化基团且具有15至40个碳原子的三酰基或疏水部分中的碳环结构的液晶硬化剂; 和d）至少一种GnRH（促性腺激素释放激素）类似物作为药理学活性物质，其中所述脂质预浓缩物以不含水流体的形式存在，并在含水流体存在下形成液晶。 药物组合物被配置为增强药理活性物质GnRH类似物的持续释放。

公开(公告)号：WO2020022659A1

公开(公告)日：2020-01-30

申请号：PCT/KR2019/007806

申请日：2019-06-27

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： AHN, Byoung Ki ,  PARK, So Hyun

IPC: A61K9/00 ,  A61K47/44 ,  A61K47/06 ,  A61K31/568 ,  A61P5/24

Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.

公开(公告)号：WO2014104788A1

公开(公告)日：2014-07-03

申请号：PCT/KR2013/012265

申请日：2013-12-27

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： YOON, Sang Phil ,  KO, Ki Seong ,  PARK, Eun Jeong ,  HONG, Sung Joon ,  PARK, So Hyun ,  KI, Min Hyo

IPC: A61K9/20 ,  A61K9/08 ,  A61K9/06 ,  A61K47/30

CPC classification number: A61K47/24 ,  A61K9/0019 ,  A61K9/107 ,  A61K31/439 ,  A61K31/69

Abstract: Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one phospholipid; c) at least one liquid crystal hardener; and d) at least one bi- or multivalent metal salt, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of anionic pharmacologically active substances through ionic interaction between the bi- or multivalent metal salt and the anionic pharmacologically active substances.

Abstract translation: 公开了一种持续释放的脂质预浓缩物，其包含：a）至少一种液晶成形剂; b）至少一种磷脂; c）至少一种液晶硬化剂; 和d）至少一种二价或多价金属盐，其中所述持续释放预浓缩物在不存在水性流体时作为脂质液相存在，并且在暴露于含水流体时形成液晶。 缓释脂质预浓缩物被配置为通过二价金属盐和阴离子药理活性物质之间的离子相互作用来增强阴离子药理学活性物质的持续释放。

公开(公告)号：WO2020204662A1

公开(公告)日：2020-10-08

申请号：PCT/KR2020/004585

申请日：2020-04-03

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： NAM, Dong Hyuk ,  LEE, Jaemin ,  PARK, So Hyun ,  KANG, Sung Kwon ,  LIM, Jong Lae

IPC: C07D211/22 ,  A61K31/445 ,  A61K9/00 ,  A61P25/28

Abstract: The present invention relates to novel donepezil myristyloxymethyl ether or a pharmaceutically acceptable salt thereof and a sustained release pharmaceutical composition comprising the same as a main ingredient. Donepezil myristyloxymethyl ether of the present invention may reduce the initial release of donepezil, which is an active ingredient, when administered into the body by introducing a myristyloxymethyl ether group into donepezil, thereby reducing the risk of side effects, such as drug toxicity and the like, and uniformly release donepezil in the body over a long period of time, thereby enhancing the therapeutic effect of the drug for patients with dementia.

公开(公告)号：WO2013032207A1

公开(公告)日：2013-03-07

申请号：PCT/KR2012/006855

申请日：2012-08-28

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP. ,  KO, Jin Young ,  KIM, Ji Yeon ,  PARK, So Hyun ,  AN, Sung Won ,  KI, Min Hyo

Inventor： KO, Jin Young ,  KIM, Ji Yeon ,  PARK, So Hyun ,  AN, Sung Won ,  KI, Min Hyo

IPC: A61K9/22 ,  A61K9/48 ,  A61K9/20 ,  A61K47/30

CPC classification number: A61K47/22 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/1075 ,  A61K31/18 ,  A61K31/58 ,  A61K31/713 ,  A61K38/26 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K48/0016

Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more -OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.

Abstract translation: 公开了一种缓释脂质预浓缩物，其包含：a）具有至少两个或更多个-OH（羟基）基团的极性头的脱水山梨糖醇不饱和脂肪酸酯; b）磷脂; 和c）不含可离子化基团的具有15至40个碳原子的疏水部分的具有三酰基或碳环结构的液晶硬化剂。 脂质预浓缩物在没有水性流体的情况下以液相形式存在，并在含水流体存在下形成液晶。 此外，还提供了还包含药理活性成分加上预浓缩物的药物组合物。